Who are Tabirafusp tedromer's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dupilumab (SAR231893), Dupilumab - Dose Reduction, Stopping dupilumab, Dupilumab therapy, Dupilumab step-down, Dupilumab Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tabirafusp-tedromer.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Tabirafusp tedromer — Competitive Intelligence Brief

Tabirafusp tedromer (Tabirafusp tedromer) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-4 receptor alpha antagonist. Area: Allergy.

phase 3 IL-4 receptor alpha antagonist IL-4Rα Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Tabirafusp tedromer (Tabirafusp tedromer) — Kodiak Sciences Inc. Tabirafusp tedromer is a fusion protein that targets the interleukin-4 receptor alpha subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tabirafusp tedromer TARGET	Tabirafusp tedromer	Kodiak Sciences Inc	phase 3	IL-4 receptor alpha antagonist	IL-4Rα
Dupilumab (SAR231893)	Dupilumab (SAR231893)	Sanofi	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab - Dose Reduction	Dupilumab - Dose Reduction	Johns Hopkins University	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Stopping dupilumab	Stopping dupilumab	University Hospital, Toulouse	marketed	Monoclonal antibody	Interleukin-4 receptor alpha subunit (IL-4Rα)
Dupilumab therapy	Dupilumab therapy	National Medical Research Center for Children's Health, Russian Federation	marketed	Monoclonal Antibody	IL-4Rα
Dupilumab step-down	Dupilumab step-down	Nantes University Hospital	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab Injectable Product	Dupilumab Injectable Product	University of Virginia	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-4 receptor alpha antagonist class)

GlaxoSmithKline · 1 drug in this class
Kodiak Sciences Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tabirafusp tedromer — Competitive Intelligence Brief. https://druglandscape.com/ci/tabirafusp-tedromer. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab